Events

Safety Alert for CATETER BD HYDROCATH

According to Agência Nacional de Vigilância Sanitária (ANVISA), this safety alert involved a device in Brazil that was produced by BECTON DICKISON.

What is this?

Alerts provide important information and recommendations about products. Even though an alert has been issued, it does not necessarily mean a product is considered to be unsafe. Safety Alerts, addressed to health workers and users, may include recalls. They can be written by manufacturers, but also by health officials.

Learn more about the data here
  • Type of Event
    Safety alert
  • Event ID
    90
  • Date
    2001-10-11
  • Event Country
    Brazil
  • Event Source
    ANVISA
  • Event Source URL
    http://www.anvisa.gov.br/sistec/alerta/consultaralerta.asp
  • Notes / Alerts
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Extra notes in the data
    BRAZIL - 11/10/2001 - INFORMS THAT PROTOCOLED TO ANVISA-NATIONAL AGENCY OF SANITARY SURVEILLANCE - BRAZIL, (PROTOCOL No. 123660/11) REQUEST FOR AMENDMENT OF PRODUCT NAME FOR BD CATHETER INTRAVENOUS CENTRAL HYDROCATH AND ACCESSORIES. ALTERATION OF LABELING: "AGAINST INDICATION - DO NOT USE IN DIFFERENT PEDIATRICS SUSPECTING IMMEDIATE REACTIONS OF TYPE HYPENSENSILITY, THE INTRAVENOUS CATHETER BD HYDROCATH SHOULD NOT BE USED IN PATIENTS WITH A WEIGHT BELOW 20 KG WARNING - HAS BEEN SUSPECTED OF CASES ISOLATED OF TYPICAL REACTIONS HYPERSENSITIVITY IN PATIENTS TREATED WITH BD HYDROCATH INTRAVENOUS CATHETER: AS A PRECAUTIONARY MEASURE, THE POSSIBILITY OF THE OCCURRENCE OF SUCH REACTIONS SHOULD BE CONSIDERED WHEN USING THIS CATHETER "
  • Reason
    Occurrence of rare cases of immediate types of hypersensitivity reactions during the use of bd hydrocath central and arterial cathederes - 1 reaction / 60,000 catheters, 80% of which is verified in pediatric cases.
  • Action
    CONSIDERING THE SUSPECTED INCIDENT, THE COMPANY HAS DECIDED TEMPORARILY TO SUSPEND THE MARKETING OF CATHETER HYDROCATH IN ALL COUNTRIES WHERE IT DID BUSINESS WHERE THAT ANALYTICAL TESTS AND RISK ASSESSMENT LEADED BY EXPERTS FROM THE HEALTH AREA OF GERMANY AND ENGLAND SEARCH THE EXISTENCE OF A RELATIONSHIP OF CASUALITY BETWEEN THE INCIDENT AND THE DEVICE. IT ALSO REPORTS, THAT BY PRECAUTION, ALERTED THE MEDICAL COMMUNITY, THROUGH * NOTICE INSERTED IN THE PACKAGE AND PROTOCOL TO ANVISA-NATIONAL AGENCY OF SANITARY SURVEILLANCE- BRAZIL, REQUEST OF ALTERATION OF LABELING. WITH THE FOLLOWING INFORMATION: * "AGAINST INDICATION - DO NOT USE IN DIFFERENT PEDIATRICS SUSPECTED OF IMMEDIATE REACTIONS OF THE TYPE HYPENSENSILITY, THE INTRAVENOUS CATHETER BD HYDROCATH SHOULD NOT BE USED IN PATIENTS WITH A WEIGHT BELOW 20 KILOS WARNING - HAS BEEN SUSPECTED OF CASES ISOLATED OF REACTIONS OF THE TYPE HYPERSENSITIVITY IN PATIENTS TREATED WITH INTRAVENOUS CATHETER BD HYDROCATH. AS A PRECAUTIONARY MEASURE, THE POSSIBILITY OF THE OCCURRENCE OF SUCH REACTIONS SHOULD BE CONSIDERED WHEN USING THIS CATHETER "

Device

CATETER BD HYDROCATH

Manufacturer

BECTON DICKISON
  • Source
    ANVSANVISA